David Berry to Deliver AAPS PharmSci 360 Address

The investor and entrepreneur will speak in New Orleans on October 28, 2026, about economics in drug development.

Updated on Oct. 26, 2026 in Healthcare

Isometric editorial illustration of a robotic lab arm holding a vial, representing the industrial infrastructure of modern pharmaceutical development. — David Berry, managing partner at Averin Capital, will discuss strategies for reducing drug development costs at the AAPS PharmSci 360 meeting in October. AI Illustration. Upload story photo >

Live Poll

Do you believe new entrepreneurial business models will successfully reduce the cost of developing new drugs?

David Berry will deliver the closing plenary address at the AAPS PharmSci 360 meeting in New Orleans on October 28, 2026. The presentation will focus on leveraging data-driven business models and infrastructure to address the high costs of drug development.

Why it matters

The session seeks to correct economic inefficiencies in the pharmaceutical sector by analyzing how emerging technologies and infrastructure investments can lower development costs. Berry intends to provide a framework for evaluating which entrepreneurial ideas can succeed in competitive markets.

David Berry has founded over 30 companies, seven of which are valued at more than $1 billion. During his tenure as CEO of Valo Health, the company raised more than $500 million.

The players

David Berry

He is a cofounder and managing partner of Averin Capital who previously served as a general partner at Flagship Pioneering and CEO of Valo Health.

AAPS PharmSci 360

This is a professional meeting focused on pharmaceutical sciences and drug development.

The details

Berry, a cofounder and managing partner of Averin Capital, will explore how modern data-driven strategies can fundamentally shift the current drug development competitive landscape. His address will specifically highlight the necessity for infrastructure investment to improve industry cost structures.

October 25, 2026: The AAPS PharmSci 360 conference begins in New Orleans.
October 28, 2026: David Berry delivers the closing plenary address.

Market Landscape

The address aligns with the industry focus of the AAPS PharmSci 360 annual meeting, which brings together scientists and investors to discuss the future of drug development. This session reflects the broader trend of applying data-driven venture models to traditional pharmaceutical infrastructure.

Attendees and industry observers may gain insights into the financial strategies expected to lower the cost of pharmaceutical research and development. These potential structural changes in drug development could influence long-term pricing models for future medical treatments.

The takeaway

Focusing on infrastructure and data-driven models is becoming essential for entrepreneurs looking to build billion-dollar pharmaceutical entities. Investors and researchers should prioritize identifying which emerging technologies offer the most scalable path toward reducing systemic development costs.